One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab.

CONCLUSION: There was a significant improvement in visual acuity and in anatomical outcomes in the switched group at 12 months after commencing treatment with aflibercept for diabetic macular oedema.
PMID: 32452251 [PubMed - as supplied by publisher]

Source: European Journal of Ophthalmology - May 25, 2020 Category: Opthalmology Authors: Lukic M, Williams G, Shalchi Z, Patel PJ, Hykin PG, Hamilton RD, Rajendram R Tags: Eur J Ophthalmol Source Type: research